UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): March 1927, 2026

THERAVANCE BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands	001-36033	98-1226628
(State or Other Jurisdiction of	(Commission File Number)	(I.R.S. Employer Identification
Incorporation)		Number)

c/o Theravance Biopharma US, LLC

901 Gateway Boulevard

South San Francisco, CA 94080

(650) 808-6000

(~~Addresses~~Address, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Share $0.00001 Par Value		TBPH		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 28.0201. ~~Results~~Other ~~of Operations and Financial Condition.~~Events

On March 1927, 2026, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, LLC and Theravance Biopharma Ireland Limited, subsidiaries of the Registrant Theravance Biopharma, Inc. (together, “Theravance”), and Mylan Ireland Limited and Viatris Specialty L.P. (~~the~~together, “~~Company~~Mylan”) ~~issued~~, entered into a ~~press~~Settlement ~~release~~Agreement ~~regarding~~(the ~~its~~“Settlement ~~financial~~Agreement”) ~~results~~with ~~for~~Mankind ~~the~~Pharma ~~quarter~~Ltd. and ~~full~~Lifestar ~~year~~Pharma ~~ended~~LLC ~~December~~(“Mankind”) relating ~~31,~~to ~~2025~~Theravance and aMylan’s ~~business~~YUPELRI® ~~update~~(revefenacin) inhalation solution. A ~~copy~~ ofTheravance ~~the~~entity ~~press~~owns ~~release~~and Mylan is ~~furnished~~the asexclusive ~~Exhibit~~sub-licensee 99of United States Patent Nos.1 to11,484,531, ~~this~~12,048,692 ~~Current~~and ~~Report~~12,285,417 (the “Patents-in-Suit”).

The ~~information~~Settlement inAgreement ~~Item~~resolves ~~2.02~~patent ~~and in Item 9.01 of this Current Report~~litigation onbrought ~~Form~~by ~~8-K,~~Theravance ~~including Exhibit 99.1, is being furnished~~ and ~~shall~~Mylan ~~not~~against beMankind ~~deemed~~pursuant ~~“filed”~~to ~~for~~ the ~~purposes~~Hatch-Waxman ofAct ~~Section~~based 18on ~~of the~~Mankind’s ~~Securities~~filing ~~Exchange Act~~ of ~~1934,~~an asabbreviated ~~amended~~new drug ~~(the~~application (“~~Securities Exchange Act of 1934~~ANDA”), orseeking ~~otherwise~~approval ~~subject~~ to ~~the~~market ~~liabilities of~~a ~~that~~generic ~~Section,~~version ~~nor~~of ~~shall~~YUPELRI® it(revefenacin) beinhalation solution ~~incorporated~~prior byto ~~reference~~expiration ~~in any filing under the Securities Act~~ of ~~1933, as amended, or~~ the ~~Securities Exchange Act of 1934, except as expressly set forth by specific reference~~ Patents-in ~~such a filing~~-Suit.

~~Item~~Under ~~9.01.~~the ~~Financial~~Settlement ~~Statements~~Agreement, Theravance and Mylan ~~Exhibits~~granted Mankind a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market Mankind’s generic version of YUPELRI® (revefenacin) inhalation solution in the United States on or after the Licensed Launch Date of April 23, 2039, subject to certain exceptions and other provisions customary for agreements of this type.

~~(d)~~As ~~Exhibits~~required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

99.1	Press Release dated March 19, 2026
104	Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)

With this Settlement Agreement, all pending Hatch-Waxman litigation relating to YUPELRI^® (revefenacin) inhalation solution has been resolved.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THERAVANCE BIOPHARMA, INC.
Date: March 19, 2026	By:	/s/ Aziz Sawaf
Date: March 30, 2026	By:	/s/ Brett Grimaud
		Aziz Sawaf
		Brett Grimaud
		Senior Vice President and Chief Financial Officer
		General Counsel

Filing Compare · Theravance Biopharma, Inc.